Damora Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Damora Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$210.87M	-$22.26M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$209.84M	-$21.44M
Net income divided by the number of shares outstanding — profit attributable to each share.	$3.98	$-18.53
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$3.98	$-18.53

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$257.60M	$14.20M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$260.53M	$17.13M
Everything the company owes — debt, unpaid bills, and other obligations.	$20.15M	$1.30M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$240.38M	$15.83M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$6.70M	-$18.60M